Project Grant P50CA302482
Award Date 8/19/25
Completion Date 7/31/30
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- This federal Project Grant award of $567,059 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of Texas MD Anderson Cancer Center. The research focuses on investigating the potential of the drug abemaciclib, alone or in combination with circular RNA silencing, to enhance anti-tumor immune responses in soft-tissue sarcomas. The study aims to elucidate the interplay between abemaciclib, circular RNAs, and immune responses using...
- The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
- This federal Project Grant award of $414,472.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the University of Texas MD Anderson Cancer Center to investigate novel treatment approaches for SMARCB1-deficient renal medullary carcinoma. The 3-year project, running from September 1, 2025 to August 31, 2028, is focused on exploring the potential of targeting neuronal mimicry in this rare and aggressive form of...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The University of Texas MD Anderson Cancer Center received a $1,007,007.84 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from September 2022 through September 2025 to investigate the complex immunological niche of bone metastasis and its role in therapy response and resistance. Through basic, applied, and advanced biomedical research efforts, the project...
- The University of Texas MD Anderson Cancer Center was awarded a $616,715 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 11, 2025. The grant supports the development of a novel "Microbial-Inspired Immune-Stimulating Antibody-Toxin Conjugate (ATC) for Cancer Immunotherapy". The project aims to engineer an ATC that combines an anti-CD47 antibody with the Listeria monocytogenes toxin LLO, linked via a cleavable linker. This ATC is...
- The University of Texas MD Anderson Cancer Center received a $2,457,127 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to support the "INHANCE: Imaging Innovation for Head and Neck Cancer Evaluation & Treatment Delivery" research project. The goal of this 5-year project, starting August 18, 2025, is to leverage advanced imaging and computational analysis to better predict, detect, prevent, and manage normal tissue injury in head and...
- The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
- The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
- This Project Grant award, valued at $152,135, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by the University of Texas Health Science Center at Houston (UTHealth) to unravel the role of the RB1 gene in regulating enhancer control and chromatin architecture governing gene transcription in osteosarcoma. The research aims to advance the scientific understanding of osteosarcoma,...